Table 4 Univariate and multivariate analyses for overall and progression-free survival
Variables (favorable factor) | OS | PFS | ||||
|---|---|---|---|---|---|---|
Univariate | Multivariate | Univariate | Multivariate | |||
p | HR (95% CI) | p | p | HR (95% CI) | p | |
Age (under 75) | 0.99 | - | - | 0.06 | - | - |
Sex (female) | 0.99 | - | - | 0.47 | - | - |
c stage (stage III [vs. IV]) | 0.62 | - | - | 0.80 | - | - |
yc stage (stages I–III [vs. IV]) | 0.61 | - | - | 0.97 | - | - |
yp stage (stages I–III [vs. IV]) | 0.19 | - | - | 0.03 | 0.40 (0.12–1.32) | 0.13 |
Prior treatment (TKI) | 0.04 | 0.06 (0.006–0.68) | 0.02 | 0.86 | - | - |
Initial serum CEA level (under 5 ng/mL) | 0.39 | - | - | 0.10 | - | - |
Preoperative serum CEA level (under 5 ng/mL) | 0.007 | 0.03 (0.002–0.41) | 0.01 | 0.04 | 0.49 (0.21–1.17) | 0.11 |
Surgical mode (lobectomy) | 0.99 | - | - | 0.25 | - | - |
Surgical mode (segmentectomy or more) | 0.99 | - | - | 0.40 | - | - |
Mediastinal lymph node dissection (yes) | 0.73 | - | - | 0.73 | - | - |
Histology (non-adenocarcinoma) | 0.11 | - | - | 0.82 | - | - |
Pathological complete response of primary lesion (yes) | 0.99 | - | - | 0.99 | - | - |
Postoperative treatment (yes) | 0.30 | - | - | 0.58 | - | - |